Holen Sie sich die Stockscreener-App
10.74
0.09%
-0.010
Handel nachbörslich:
10.74
Schlusskurs vom Vortag:
$10.75
Offen:
$10.6
24-Stunden-Volumen:
886.98K
Relative Volume:
1.03
Marktkapitalisierung:
$737.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.66M
KGV:
-4.9953
EPS:
-2.15
Netto-Cashflow:
$-83.73M
1W Leistung:
+2.87%
1M Leistung:
+38.22%
6M Leistung:
+164.53%
1J Leistung:
-8.44%
1-Tages-Spanne:
$10.41
$11.06
1-Wochen-Bereich:
$10.28
$11.34
52-Wochen-Spanne:
$2.86
$13.51
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Vergleichen Sie OLMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
10.74 | 737.82M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Visual trend scoring systems applied to Olema Pharmaceuticals Inc.2025 Earnings Surprises & High Accuracy Investment Entry Signals - newser.com
How sustainable is Olema Pharmaceuticals Inc. stock dividend payoutWeekly Trading Summary & Expert Verified Movement Alerts - newser.com
Published on: 2025-10-13 10:23:49 - newser.com
Published on: 2025-10-13 10:17:27 - newser.com
Using flow based indicators on Olema Pharmaceuticals Inc.Earnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Has Olema Pharmaceuticals Inc. found a price floor2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Institutional scanner results for Olema Pharmaceuticals Inc.July 2025 PostEarnings & AI Based Buy/Sell Signal Reports - newser.com
Why Olema Pharmaceuticals Inc. stock attracts global investorsWeekly Earnings Recap & Fast Exit/Entry Strategy Plans - newser.com
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 5.7%What's Next? - MarketBeat
Weiss Ratings Reiterates Sell (D-) Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Can momentum traders help lift Olema Pharmaceuticals Inc.2025 Performance Recap & Fast Momentum Entry Tips - newser.com
Guggenheim Begins Coverage on Olema Pharmaceuticals (NASDAQ:OLMA) - Defense World
Does Olema Pharmaceuticals Inc. fit your quant trading modelEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Is now a turning point for Olema Pharmaceuticals Inc.2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
Will Olema Pharmaceuticals Inc. benefit from macro trendsMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
Farther Finance Advisors LLC Grows Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - Defense World
Guggenheim Initiates Coverage on OLMA with a 'Buy' Rating and $2 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Guggenheim initiates coverage on Olema Pharmaceuticals stock with Buy rating - Investing.com
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $24.00 - Defense World
What analysts say about Olema Pharmaceuticals Inc stockAnalyst Upgrades & Low Cost Portfolio Ideas - earlytimes.in
How moving averages guide Olema Pharmaceuticals Inc. tradingStop Loss & Stock Portfolio Risk Control - newser.com
How analysts rate Olema Pharmaceuticals Inc. stock todayEarnings Growth Report & Expert Verified Movement Alerts - newser.com
Will Olema Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Profit Review & Step-by-Step Swing Trade Plans - newser.com
How to forecast Olema Pharmaceuticals Inc. trends using time seriesJuly 2025 Spike Watch & Weekly Chart Analysis and Trade Guides - newser.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Metastatic HR+/HER2− Breast Cancer Market Positioned For Accelerated Development Through 2034, Delveinsight Finds Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro - Menafn.com
Metastatic HR+/HER2− Breast Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Arvinas, Olema Pharma, Sichuan Baili Pharma, Ana C Garrido-Castro - Barchart.com
Metastatic HR+/HER2 Breast Cancer Market Positioned - openPR.com
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Chart based exit strategy for Olema Pharmaceuticals Inc.Watch List & Stepwise Entry and Exit Trade Signals - newser.com
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
77,000-share award: Olema Pharmaceuticals grants stock options at $11.04 as inducement - Stock Titan
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 6.3%Time to Sell? - MarketBeat
Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) - Insider Monkey
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):